Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - Priority Announcement: Cystic fibrosis across the lifespan

University of Toronto

$50,000.00

Investigating complex genetic and epigenetic variations across the genome using long-read sequencing

EF 2024-25

Résumé
Cystic fibrosis (CF) is a life-limiting inherited disease caused by deleterious changes in a gene called CFTR. However, the severity of symptoms varies in people with the same CF causing changes partly due to other genes in an individual's genetic background, known as modifier genes. We have conducted large studies of Canadians with CF that have identified regions of the genome harbouring modifier genes for CF severity and response to medications. We have also developed statistical tools that can pinpoint the responsible modifier gene in some of these regions and how changes in the gene contribute to CF. However, some of the regions identified contain genomic sequence that is very complicated, containing large repetitive sequences, insertions, deletions or inversions. To investigate these complex regions, we have been using sequencing technologies designed to resolve these complexities, sequencing ~20,000 bases of the genome and simultaneously estimating whether the DNA is silenced or transcribed (i.e. DNA methylation levels). DNA methylation is a chemical modification at specific locations on DNA sequence that can be influenced by genetic variation affecting how genes function. It also changes with age in a process known as epigenetic aging. We hypothesize that epigenetic aging is accelerated in people with CF and could be a useful biomarker for tracking disease severity. Here, we aim to create comprehensive catalogs of complex genetic variation in the genome including repeats, insertions, deletions, and inversions along with their DNA methylation levels and effects on gene expression. Creating this catalog will also require us to develop new analytical methods and tools. We will use these resources to improve our understanding of how modifier genes contribute to CF disease severity, which may lead to new targets for medicines. We expect that these tools and catalogues will also contribute to improved understanding of other complex human genetic diseases.
Programme
Project Grant - Priority Announcement: Cystic fibrosis across the lifespan
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
526832
Name
Strug Lisa J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Cystic Fibrosis Canada
Instname2
Genetics
Theme2
Biomedical
Prcname2
Genomics: Systems and computational biology
Projecttitle
Investigating complex genetic and epigenetic variations across the genome using long-read sequencing
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$50,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Cystic fibrosis across the lifespan
Keyworddelim
Cystic Fibrosis; Dna Methylation; Genetic Association; Long-Read Sequencing; Phase; Statistical Genetics; Structural Variation
Abstract
Cystic fibrosis (CF) is a life-limiting inherited disease caused by deleterious changes in a gene called CFTR. However, the severity of symptoms varies in people with the same CF causing changes partly due to other genes in an individual's genetic background, known as modifier genes. We have conducted large studies of Canadians with CF that have identified regions of the genome harbouring modifier genes for CF severity and response to medications. We have also developed statistical tools that can pinpoint the responsible modifier gene in some of these regions and how changes in the gene contribute to CF. However, some of the regions identified contain genomic sequence that is very complicated, containing large repetitive sequences, insertions, deletions or inversions. To investigate these complex regions, we have been using sequencing technologies designed to resolve these complexities, sequencing ~20,000 bases of the genome and simultaneously estimating whether the DNA is silenced or transcribed (i.e. DNA methylation levels). DNA methylation is a chemical modification at specific locations on DNA sequence that can be influenced by genetic variation affecting how genes function. It also changes with age in a process known as epigenetic aging. We hypothesize that epigenetic aging is accelerated in people with CF and could be a useful biomarker for tracking disease severity. Here, we aim to create comprehensive catalogs of complex genetic variation in the genome including repeats, insertions, deletions, and inversions along with their DNA methylation levels and effects on gene expression. Creating this catalog will also require us to develop new analytical methods and tools. We will use these resources to improve our understanding of how modifier genes contribute to CF disease severity, which may lead to new targets for medicines. We expect that these tools and catalogues will also contribute to improved understanding of other complex human genetic diseases.
Competitiondate
202503
Approvedterm2
1 yr 0 mth
Pinamesdelim
Strug, Lisa J
Approvedterm
1 an 0 mois
Cihrcontribution2
ICRH~ $50,000~ $0~